You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

561 Results
Guidelines and Advice
Status: Current
ID: GL 12-10
Version: 2
Jul 2019
Guidelines and Advice
Status: Current
ID: PET 2018-2
Jul 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lorlatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Drug
Other Name(s): Cabometyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Guidelines and Advice
Status: Current
ID: GL 3-20
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
Version: 1
Apr 2019
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019

Pages